Short answer
Janux Therapeutics, Inc. (JANX) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $4M with net income of −$24M.
Q1 2026 key financials · XBRL
- Revenue
- $4M
- Net income
- −$24M
- −3.6% YoY
- Operating margin
- -916.5%
- EPS (diluted)
- −$0.39
- −2.6% YoY
Source: XBRL data from the Janux Therapeutics, Inc. (JANX) Q1 2026 10-Q on SEC EDGAR. USD.
Janux Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $3.7M vs $0 YoY; no product sales
- Operating margin -34.2% vs -34.9% YoY; net loss $24.4M vs $23.5M
- JANX007 R&D costs $5.3M, highest named program; JANX011 $1.3M, down $1.3M YoY
- Cash, equivalents, restricted cash and short-term investments $957.2M; operating cash use $12.3M vs $17.0M
- Cash expected to fund operations at least 12 months; expenses and losses expected to increase substantially
Risk Factors
- JANX008 discontinuation in April 2026 after Phase 1a, reflecting insufficient activity versus other pipeline programs
- Net loss $24.4 million for Q1 2026 versus $23.5 million in Q1 2025, with continued losses expected
- Cash, cash equivalents and short-term investments $956.4 million as of March 31, 2026, funding operations at least 12 months
- Regulatory approval uncertainty for novel technologies, including potential additional trials or narrower indications
- Competitive risk from rapidly developing immuno-oncology technologies potentially reducing platform value
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Janux Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.